(Total Views: 632)
Posted On: 03/15/2025 5:15:46 PM
Post# of 154759
This data Vs., is Leronlimab becoming oncology SOC:
TRODELVY (sacituzumab govitecan)
267 patients trial.
Half of those who received TRODELVY lived nearly 12 months.
*63% of patients had a treatment interruption due to side effects
*27% of people receiving TRODELVY experienced serious adverse reactions.
*22% of patients had a dose reduction to help manage side effects
*5% of patients discontinued TRODELVY due to side effects
trodelvy.com/patient/mtnbc/...
Cytodyn:
cytodyn.com/newsroom/press-...
Waiting to announce non-toxic Leronlimab having cured cancer.
TRODELVY (sacituzumab govitecan)
267 patients trial.
Half of those who received TRODELVY lived nearly 12 months.
*63% of patients had a treatment interruption due to side effects
*27% of people receiving TRODELVY experienced serious adverse reactions.
*22% of patients had a dose reduction to help manage side effects
*5% of patients discontinued TRODELVY due to side effects
trodelvy.com/patient/mtnbc/...
Cytodyn:
cytodyn.com/newsroom/press-...
Waiting to announce non-toxic Leronlimab having cured cancer.
(12)
(0)
